文献速递膀胱癌与上尿路尿路上皮癌

中危非肌层浸润性膀胱癌的监测强度:重新审视膀胱镜检查的最佳时机与频率

Surveillance Intensity in Intermediate Risk, Nonmuscle Invasive Bladder Cancer: Revisiting the Optimal Timing and Frequency of Cystoscopy.
PubMed 文献 · J Urol · 2021-02-22

该回顾性研究纳入107例中危非肌层浸润性膀胱癌患者,比较3个月(高强度)、6个月(中强度)和12个月(低强度)三种膀胱镜监测模型。结果显示高强度监测虽能更快发现复发,但成本更高且可避免的膀胱镜检查更多,而无明确肿瘤学获益;中强度(6个月)监测可及时检出且不损害肿瘤学结局,成本更低。

要点

  • 中危NMIBC采用6个月膀胱镜监测可及时检出复发且不增加肿瘤学风险。
  • 3个月高强度监测成本更高且可避免的膀胱镜检查更多,无明确肿瘤学获益。
  • 12个月低强度监测延迟复发和进展检出更明显,不推荐。

核心结论

  • 高强度(3个月)监测可更快发现复发,但成本增加、可避免的膀胱镜检查更多,且无明确肿瘤学获益。
  • 中危NMIBC采用中强度(6个月)监测可及时检出复发和进展,不损害肿瘤学结局,且成本更低、膀胱镜检查更少。

研究设计与样本

  • 回顾性分析2010-2017年中危非肌层浸润性膀胱癌患者107例,中位随访37个月。
  • 应用三种假设监测模型:模型1高强度(3个月)、模型2中强度(6个月)、模型3低强度(12个月),为期2年。
  • 比较实际复发和进展检出时机与各模型提议的膀胱镜时机,计算可避免的膀胱镜检查次数及相关成本。

主要发现

  • 107例中66例(77.6%)发生复发,12例(14.1%)发生进展。
  • 相对模型1,模型2有33例(50%)复发检出延迟,模型3有41例(62%)延迟。
  • 模型1 vs 3复发检出平均延迟1.7个月 vs 3.2个月,模型2和3延迟7.6个月(模型1 vs 2 p<0.001;模型2 vs 3 p<0.001)。
  • 相对模型1,模型2和3分别有8例(67%)和9例(75%)进展事件检出延迟。
  • 无因延迟检出导致的进展相关膀胱癌死亡或根治性膀胱切除术。

临床怎么用

  • 中危NMIBC可考虑采用6个月间隔的膀胱镜监测,以平衡检出及时性与成本。
  • 避免常规使用3个月高强度监测,因其增加成本和可避免的检查而无明确肿瘤学获益。

局限性

  • 回顾性研究设计。
  • 样本量较小(107例)。
  • 单中心数据可能影响普适性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We sought to determine the optimal cystoscopic interval for intermediate risk, nonmuscle invasive bladder cancer. MATERIALS AND METHODS: A retrospective analysis of patients with intermediate risk, nonmuscle invasive bladder cancer (2010-2017) was performed and 3 hypothetical models of surveillance intensity were applied: model 1: high (3 months), model 2: moderate (6 months) and model 3: low intensity (12 months) over a 2-year period. We compared timing of actual detection of recurrence and progression to proposed cystoscopy timing between each model. We calculated number of avoidable cystoscopies and associated costs. RESULTS: Of 107 patients with median followup of 37 months, 66/107 (77.6%) developed recurrence and 12/107(14.1%) had progression. Relative to model 1, there were 33 (50%) delayed detection of recurrences in model 2 and 41 (62%) in model 3. There was a 1.7-month mean delay in detection of recurrence for model 1 vs 3.2, and a 7.6-month delay for models 2 and 3 (p <0.001 model 1 vs 2; p <0.001 model 2 vs 3). Relative to model 1, there were 8 (67%) and 9 (75%) delayed detection of progression events in model 2 and 3. There were no progression-related bladder cancer deaths or radical cystectomies due to delayed detection. Mean number of avoidable cystoscopies was higher in model 1 (2) vs model 2 (1) and 3 (0). Model 1 had the highest aggregate cost of surveillance ($46,262.52). CONCLUSIONS: High intensity (3-month) surveillance intervals provide faster detection of recurrences but with increased cost and more avoidable cystoscopies without clear oncologic benefit. Moderate intensity (6-month) intervals in intermediate risk, nonmuscle invasive bladder cancer allows timely detection without oncologic compromise and is less costly with fewer cystoscopies.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Bhat A, Kwon D, Soodana-Prakash N, et al. Surveillance Intensity in Intermediate Risk, Nonmuscle Invasive Bladder Cancer: Revisiting the Optimal Timing and Frequency of Cystoscopy. J Urol. 2021. PMID: 33617331. doi:10.1097/JU.0000000000001689

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。